Testing a new PNH pill for people who haven't had complement therapy
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests a new oral medication called MY008211A for people with PNH who have not yet tried complement inhibitors. It aims to improve anemia and reduce the need for blood transfusions by targeting the part of the immune system that destroys red blood cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and have a BMI of 18 or higher.
- Your PNH must affect at least 10% of your red blood cells (confirmed by a special blood test).
- You must have low hemoglobin (less than 100 g/L) and high LDH (a marker of red blood cell breakdown) at screening.
- You must receive a meningitis vaccine before starting the study. Vaccines for certain other infections are also recommended if you haven't had them.
- You cannot have had a stem cell or bone marrow transplant, or your spleen removed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
This trial is testing an experimental pill called NTQ5082 for people with PNH who haven't been treated with complement inhibitors before. The goal is to see if it can improve anemia and control PNH symptoms like fatigue and blood clots.
This trial tests a new medicine, XH-S003, for people with paroxysmal nocturnal hemoglobinuria (PNH) who have not tried complement inhibitors before. The goal is to see if it can help manage symptoms like low red blood cells and fatigue.
This study tests a new pill (FXS6837) against a standard treatment (eculizumab) for people with PNH. The goal is to see if the pill is safe and effective in improving anemia and reducing the need for transfusions.
This trial tests an experimental drug called SGB-9768 that may help people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that causes red blood cells to break down. The drug aims to control the disease and improve blood counts, which may reduce symptoms like fatigue and anemia.
This study tests a new medicine called VSA012 for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease. The goal is to see if VSA012 can help manage symptoms like fatigue and low blood counts better than the current standard treatment.
Hear when a new Paroxysmal Nocturnal Haemoglobinuria (PNH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.